Biohaven Pharmaceutical Holding Co Ltd (BHVN) Rating Reiterated by William Blair
Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN)‘s stock had its “outperform” rating reaffirmed by analysts at William Blair in a report released on Tuesday.
BHVN has been the topic of several other reports. Zacks Investment Research lowered shares of Biohaven Pharmaceutical Holding Co from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th. BidaskClub upgraded Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. Piper Jaffray Companies reissued a “buy” rating and issued a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, September 12th. Needham & Company LLC reissued a “buy” rating and issued a $43.00 price objective (up previously from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a report on Wednesday, September 13th. Finally, Morgan Stanley boosted their price objective on Biohaven Pharmaceutical Holding Co from $28.00 to $47.00 and gave the company an “overweight” rating in a report on Monday, September 25th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $40.80.
Shares of Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) traded down 6.97% during trading on Tuesday, reaching $33.08. The company had a trading volume of 642,315 shares. The company’s 50 day moving average is $35.13 and its 200-day moving average is $27.61. The stock’s market capitalization is $1.19 billion. Biohaven Pharmaceutical Holding Co has a 1-year low of $17.00 and a 1-year high of $39.51.
TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/03/biohaven-pharmaceutical-holding-co-ltd-bhvn-rating-reiterated-by-william-blair.html.
Biohaven Pharmaceutical Holding Co Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Stock Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related stocks with our FREE daily email newsletter.